Ultragenyx Pharma (RARE) Misses Q4 EPS by 45c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.79), $0.45 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $83.4 million versus the consensus estimate of $83.79 million.

GUIDANCE:

The company expects 2022 revenue for Crysvita in Ultragenyx territories to be between $250 million and $260 million and Dojolvi revenue to be between $55 million and $65 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
• Marpai, Inc. (MRAI) Misses Q2 EPS by 18c